Rapid triple-detection test speeds flu and COVID-19 diagnosis

QuidelOrtho Corporation is broadening its point-of-care diagnostic offerings with the launch of the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid immunoassay designed for use in physician office laboratories, urgent care centres, emergency departments, pharmacies, and decentralised hospital labs.

The new test provides simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample, delivering results in as fast as 10–15 minutes. By helping clinicians quickly distinguish between flu and COVID-19 - two respiratory illnesses with overlapping symptoms - the test supports faster treatment decisions, improved patient outcomes, and reduced community spread.

Designed for professional use, the QUICKVUE Influenza + SARS Test combines an easy-to-collect nasal swab with a streamlined processing workflow and a clear visual readout. Its rapid turnaround and cost-effective design make it an accessible tool for a variety of healthcare settings, without the need for instrument-based testing.

“Frontline clinicians need reliable tools to manage respiratory illness surges,” said Tammi Ranalli, PhD, Senior VP, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho. “The QUICKVUE Influenza + SARS Test equips healthcare professionals with a fast, accurate, and efficient solution to guide care decisions during peak flu and COVID-19 seasons.”

The launch complements QuidelOrtho’s existing SOFIA™ 2 Flu + SARS Antigen FIA platform, offering a visually read option alongside instrument-based testing and reinforcing the company’s leadership in point-of-care respiratory diagnostics. The QUICKVUE Influenza + SARS Test is available across the United States through QuidelOrtho’s established distribution channels. 

More information online